Matches in Wikidata for { <http://www.wikidata.org/entity/Q97544821> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- Q97544821 description "article scientifique publié en 2020" @default.
- Q97544821 description "artículu científicu espublizáu en xunetu de 2020" @default.
- Q97544821 description "im Juli 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q97544821 description "scientific article published on 14 July 2020" @default.
- Q97544821 description "wetenschappelijk artikel" @default.
- Q97544821 description "наукова стаття, опублікована 14 липня 2020" @default.
- Q97544821 name "Comparison of the efficacy and safety of the EC-T (epirubicin/cyclophosphamide followed by docetaxel) and TCb (docetaxel/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-III breast cancer" @default.
- Q97544821 name "Comparison of the efficacy and safety of the EC-T (epirubicin/cyclophosphamide followed by docetaxel) and TCb (docetaxel/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-III breast cancer" @default.
- Q97544821 type Item @default.
- Q97544821 label "Comparison of the efficacy and safety of the EC-T (epirubicin/cyclophosphamide followed by docetaxel) and TCb (docetaxel/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-III breast cancer" @default.
- Q97544821 label "Comparison of the efficacy and safety of the EC-T (epirubicin/cyclophosphamide followed by docetaxel) and TCb (docetaxel/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-III breast cancer" @default.
- Q97544821 prefLabel "Comparison of the efficacy and safety of the EC-T (epirubicin/cyclophosphamide followed by docetaxel) and TCb (docetaxel/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-III breast cancer" @default.
- Q97544821 prefLabel "Comparison of the efficacy and safety of the EC-T (epirubicin/cyclophosphamide followed by docetaxel) and TCb (docetaxel/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-III breast cancer" @default.
- Q97544821 P1433 Q97544821-A64CEEAE-6158-49E4-B499-BED5ABF009AB @default.
- Q97544821 P1476 Q97544821-E31565DC-8559-448D-B01E-706406E5AEC8 @default.
- Q97544821 P2093 Q97544821-1BA1492E-7142-4DC2-8377-85274C5DAFF4 @default.
- Q97544821 P2093 Q97544821-3A235CC6-929A-411A-AE68-F66379137237 @default.
- Q97544821 P2093 Q97544821-4CF1852C-63F1-408D-AA4E-2D9FD90A288C @default.
- Q97544821 P2093 Q97544821-4FD44D61-96DB-45D9-B579-D3D5481F3E02 @default.
- Q97544821 P2093 Q97544821-87D7FE18-B965-40E9-BD9F-7998FA6E97A4 @default.
- Q97544821 P2093 Q97544821-89CF03B3-B589-4339-BF99-5361E780E441 @default.
- Q97544821 P2093 Q97544821-9AF650B8-DC4A-4AC8-8271-05C6ABB19289 @default.
- Q97544821 P2093 Q97544821-B2889FDC-91AF-462A-96D9-13BA21B9488C @default.
- Q97544821 P2093 Q97544821-C17B86A4-ABA6-4D28-A3AE-2CAB35F3B573 @default.
- Q97544821 P2093 Q97544821-E2A8AD6A-1F86-4B32-8423-33AC56340BF2 @default.
- Q97544821 P2093 Q97544821-F5D1AFAA-6EE7-4FF3-9453-E7F22CFA5ECA @default.
- Q97544821 P31 Q97544821-922B58F3-5F36-4A72-B7B0-EA5680C9D985 @default.
- Q97544821 P356 Q97544821-DB24246B-C6C9-4C0E-A0CA-BEB2D037FD5A @default.
- Q97544821 P577 Q97544821-4C9EBCC7-F439-4C3F-9243-606683C87681 @default.
- Q97544821 P698 Q97544821-E1C49B16-C35E-4EF2-B2BB-E12394A81726 @default.
- Q97544821 P921 Q97544821-1B183AC6-68DB-4D9D-937D-82BF64B66925 @default.
- Q97544821 P356 NEO_2020_200130N96 @default.
- Q97544821 P698 32657611 @default.
- Q97544821 P1433 Q15761100 @default.
- Q97544821 P1476 "Comparison of the efficacy and safety of the EC-T (epirubicin/cyclophosphamide followed by docetaxel) and TCb (docetaxel/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-III breast cancer" @default.
- Q97544821 P2093 "C Q Yang" @default.
- Q97544821 P2093 "F Ji" @default.
- Q97544821 P2093 "F P Xu" @default.
- Q97544821 P2093 "H F Gao" @default.
- Q97544821 P2093 "K Wang" @default.
- Q97544821 P2093 "L L Zhang" @default.
- Q97544821 P2093 "M X Hu" @default.
- Q97544821 P2093 "M Y Cheng" @default.
- Q97544821 P2093 "M Yang" @default.
- Q97544821 P2093 "T Zhu" @default.
- Q97544821 P2093 "W P Li" @default.
- Q97544821 P31 Q13442814 @default.
- Q97544821 P356 "10.4149/NEO_2020_200130N96" @default.
- Q97544821 P577 "2020-07-14T00:00:00Z" @default.
- Q97544821 P698 "32657611" @default.
- Q97544821 P921 Q420436 @default.